Who is sponsoring NCT05145660?

NCT05145660 is sponsored by Jun-Lin Yi, MD.

What drugs are being tested in NCT05145660?

Interventions in NCT05145660: intensity-modulated radiotherapy (IMRT) with reduced-volume, Chemotherapy.

What condition does NCT05145660 study?

NCT05145660 studies Nasopharyngeal Carcinoma.

Is NCT05145660 still recruiting?

NCT05145660 is currently recruiting now. Last updated 27 September 2022.

Last reviewed 2022-09-27 · How we verify

NCT05145660

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC

Recruiting now Phase 3 Last updated 27 September 2022

What this trial tests

Phase 3 trial testing intensity-modulated radiotherapy (IMRT) with reduced-volume in Nasopharyngeal Carcinoma in 414 participants. Currently enrolling.

Timeline

1 September 2022

Primary endpoint
31 August 2027

31 August 2027

Quick facts

Lead sponsor	Jun-Lin Yi, MD
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	414
Start date	1 September 2022
Primary completion	31 August 2027
Estimated completion	31 August 2027
Sites	1 location across China

Drugs / interventions tested

intensity-modulated radiotherapy (IMRT) with reduced-volume
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Jun-Lin Yi, MD

Who can join

Adults 18 to 75, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Current radiotherapy guidelines and consensus statements uniformly recommend elective region irradiation (ERI) as the standard strategy for nasopharyngeal carcinoma (NPC). However, given the scarcity of skip-metastasis, the improved assessment accuracy of nodal involvement, and the striking advancements in chemotherapy for NPC, a one-fits-all delineation scheme for clinical target volumes for the nodal region (CTVn) may not be appropriate anymore, and modifications of the CTVn delineation strategy may be warranted. Involved site irradiation (ISI) covering merely the initially involved nodal site and potential extranodal extension has been confirmed to be as effective as ERI with decreased radiation-related toxicities in some malignancies, but has not yet been investigated in NPC. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of ISI with conventional ERI in NPC patients with a limited nodal burden.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The evolution of prophylactic neck irradiation in nasopharyngeal carcinoma: Changing concepts and irradiation ranges.
Liao W, Zhao Y, Zhang S. · · 2025 · cited 2× · PMID 41163975 · DOI 10.1002/pro6.70007
Involved site radiation therapy in stage I-III nasopharyngeal carcinoma with limited lymph node burden (ISRT-NPC) or elective region irradiation: a study protocol for a multicenter non-inferiority randomized controlled phase III clinical trial.
Liu Y, Han Y, Liu F, Hu D, et al · · 2023 · PMID 37537541 · DOI 10.1186/s12885-023-11212-7

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05145660 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jun-Lin Yi, MD
Last refreshed: 27 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing